GERD

26

Review clinical trials related to GERD. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

The Effect of the Reflux Band™ Upper Esophageal Sphincter (UES) Assist Device on Reflux for Lung Transplant Recipients

A prospective, open label, study designed to assess the affect of the Reflux Band® UES Assist Device (Reflux Band) on reflux in patients that have undergone lung transplantation.

Participants needed: 20
Trial details
Age: 18-80Biological sex: AllType: InterventionalSponsor: University of FloridaUpdated: Jul 13, 2026Locations: 1
Eligibility criteria

Clinically stable lung transplant patients(single lung, double lung, or re-trans... [+3]

Currently being treated with another investigational medical device and/or drug [+5]

Status: Not yet recruiting

Antireflux Surgery Without Preoperative Esophageal Manometry

The goal of this clinical trial is to learn if people can safely skip a test called esophageal manometry before surgery for acid reflux (gastroesophageal reflux disease, or GERD) or a hiatal hernia. Manometry measures the muscles of the food pipe using a thin tube passed through the nose. The test can be uncomfortable and can delay surgery. The main questions this study aims to answer are whether people can skip manometry and still have good swallowing one year after surgery, and whether skipping the test lowers discomfort, shortens the wait for surgery, and lowers cost. To answer this, researchers will compare two groups. One group will have surgery without manometry. The other group will have manometry first, the way it is usually done. Everyone will get the same operation, a partial wrap called a Toupet fundoplication, so the study tests the value of the test and not the surgery. Participants will be placed by chance into one of the two groups, have the same standard operation, and fill out short questionnaires about their swallowing before surgery and again at 3, 6, and 12 months after surgery. Researchers want to find out if skipping manometry works just as well as the usual approach for people who do not have trouble swallowing before surgery.

Participants needed: 96
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: McMaster UniversityUpdated: Jun 22, 2026Locations: 2
Eligibility criteria

Age ≥ 18 years [+9]

Overt dysphagia (Mellow-Pinkas ≥ 1 or Eckardt ≥ 1) [+10]

Status: Recruiting

A Study to Investigate the Pharmacokinetics and ECG Effects of Linaprazan Glurate

This is a Phase I, single-center, double blind, placebo-controlled, parallel-group, randomized trial designed to evaluate the PK, cardiodynamic ECG effects, safety, and tolerability of single oral doses of linaprazan glurate. The trial will explore the PK properties of linaprazan glurate and linaprazan as well as the cardiodynamic ECG effects, safety, and tolerability after the administration of single doses: 300 mg and 600 mg in Part I of the trial, using formulation A of linaprazan glurate, as well as 150 mg, 275 mg, and up to 2 additional dose levels, using formulation C of linaprazan glurate to reach target linaprazan mean Cmax exposure (5222 nmol/L).

Participants needed: 121
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Cinclus Pharma Holding ABUpdated: Jun 17, 2026Locations: 1
Eligibility criteria

Willing and able to give written informed consent for participation in the study... [+3]

Female subjects of childbearing potential unless they agree to use highly effect... [+4]

Status: Recruiting

Famotidine and Antacids for Treatment of Dyspepsia

The aim of this study is to compare intravenous famotidine, an H2 receptor antagonist, and Maalox/ Mylanta, an oral antacid, in treatment of dyspepsia in the emergency department. The goal of this study is to reduce patients' pain based on the verbal numerical pain scale. The anticipated outcome is for pain levels in both groups to decrease. It is expected that antacids will improve symptoms more quickly and to a greater degree within an hour of taking medication based on the results of similar studies.

Participants needed: 80
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Stony Brook UniversityUpdated: Jun 2, 2026Locations: 1
Eligibility criteria

Subject Age ≥ 18 years of age [+2]

Hypersensitivity to an ingredient in Maalox/ Mylanta or Famotidine [+7]

Status: Recruiting

Transoral Incisional Fundoplication (TIF) for Patients Suffering From Gastroesophageal Reflux Disease in an Asian Population

Transoral incisionless fundoplication (TIF) has become a widely used intervention to restore the valve at the gastroesophageal junction in selected patients suffering from gastroesophageal reflux disease (GERD). More than 20,000 procedures have been performed worldwide. TIF with EsophyX device reconfigures the tissue to establish an omega-shaped full-thickness gastroesophageal valve from inside the stomach. The procedure creates serosa to serosa plications which include the muscle layers and constructs valves 3-5cm long, taking in 200-270 degrees of the circumference, and deploying multiple non-absorbable polypropylene fasteners through the two layers in a circumferential patten around the gastroesophageal junction. Data so far indicate that, in the majority of patients, the procedure achieves lasting improvement in GERD symptoms measured by either pH or impedance monitoring. The technique offers an acceptable alternative to surgery, mimicking partial fundoplication, but less invasive and with no persistent side effects, in patients with proven pathological GERD with either a competent gastroesophageal valve or hiatal hernia, not longer than 3cm, who refuse, are intolerance, or are unresponsive to PPI maintenance therapy. Laparoscopic fundoplication, although still considered to be the gold-standard approach for GERD refractory to medical treatment, does involve some risk of long-term adverse events such as dysphagia (5-12%), inability to vomit or belch, gas/bloat syndrome (19%) and excessive flatulence. Several prospective observational studies and some comparative trials have proved efficacy of TIF with EsophyX in obtaining a significant reduction in the acid exposure time (AET) assessed by esophageal 24-hour pH-impedance monitoring versus sham, and in controlling both typical and atypical GERD symptoms for up to 1 to 2 years, as reported in a meta-analysis7. Outcomes at 3, 5, and 10 years have been reported in different studies and showed to be favourable. In an Italian study reporting the 10 year follow-up, the GERD-HRQL score, heartburn and regurgitation score were significantly lower than pre-procedure and did not change significantly during the follow-up. The rates of patients who had stopped or halved anti-secretive therapy 2, 3, 5, 7 and 10 years after the procedure were 86.7%, 84.4%, 73.5%, 83.3% and 91.7% respectively. This procedure, however, has not been performed in Asia patients. Asians have smaller body build and is known to have less GERD when compared to the Caucasian population. This study, therefore, is a feasibility study to perform TIF in an Asian population. In patients who fulfil the inclusion criteria, TIF will be performe under general anaesthesia. They will then be followed-up at 4 weeks, 3 months, then yearly for up to 5 years after the procedure. The anti-reflux control and adverse events will be recorded.

Participants needed: 20
Trial details
Phase: Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Chinese University of Hong KongUpdated: Apr 29, 2026Locations: 1
Eligibility criteria

18 years - 80 years of age [+3]

Systemic disease not well controlled [+11]

Status: Recruiting

Vonaprazan Versus Esomeprazole for Healing of LA Grade B or Higher Esophagitis After POEM

Peroral Endoscopic Myotomy (POEM) is a well-established treatment for achalasia; however, it is frequently associated with gastroesophageal reflux disease (GERD), with many patients developing LA grade B or higher esophagitis. Proton pump inhibitors (PPIs) like Esomeprazole are the standard treatment, but Vonaprazan, a potassium-competitive acid blocker (P-CAB), offers superior acid suppression and may provide enhanced healing in post-POEM reflux esophagitis. Primary Objective: • To compare the healing rates of LA grade B or higher reflux esophagitis at 8 weeks in patients receiving Vonaprazan 20 mg versus Esomeprazole 40 mg. Secondary Objectives * To assess improvement in reflux symptoms using the GERD-Q score at 8 weeks. * To evaluate the incidence of adverse events in each treatment group.

Participants needed: 300
Trial details
Age: 18-75Biological sex: AllType: InterventionalSponsor: Asian Institute of Gastroenterology, IndiaUpdated: Apr 27, 2026Locations: 1
Eligibility criteria

Age ≥18 years [+4]

History of prior anti-reflux surgery [+5]

Status: Recruiting

Diaphragmatic Training on GERD

he goal of this clinical trial is to evaluate the effects of diaphragm-oriented breathing training on patients with gastroesophageal reflux disease (GERD). This study will compare two non-invasive respiratory interventions-diaphragmatic breathing exercise (DBE) and volume-oriented incentive spirometry (VIS)-in terms of their impact on esophageal function and health-related quality of life.The main questions it aims to answer are:Does DBE or VIS improve GERD symptoms as measured by the GERD Questionnaire (GERDQ)?Do these interventions reduce esophageal acid exposure time and the number of reflux episodes?Do these interventions improve lower esophageal sphincter (LES) pressure and esophageal motility?Do these interventions improve GERD-related quality of life as measured by the GERD-HRQL questionnaire?Researchers will compare three groups: DBE, VIS, and a control group receiving standard care, to determine whether diaphragm-oriented breathing training provides additional benefits over usual management.Participants will:Be randomly assigned to one of three groups (DBE, VIS, or control)Perform the assigned intervention for 6 weeksUndergo baseline and post-intervention assessments, including symptom questionnaires and esophageal function testing Record symptoms and adherence in a daily diary

Participants needed: 42
Trial details
Age: 20-80Biological sex: AllType: InterventionalSponsor: Changhua Christian HospitalUpdated: Apr 22, 2026Locations: 1
Eligibility criteria

Age between 20 and 80 years.2. A confirmed diagnosis of gastroesophageal reflux... [+4]

Pregnant or breastfeeding women. [+3]

Status: Recruiting

PRospective Registry of Esophageal Motility

Digestive physiopathology is a branch of gastroenterology aiming to study patients with upper GI symptoms, mainly gastro-esophageal, potentially indicating the presence of Gastroesophageal Reflux Disease (GERD)/Barrett Esophagus (BE) or obstructive esophageal motility disorders (achalasia being the most relevant), but including also other primary motility disorders such as Esophgago-Gastric Junction Outflow Obstruction (EGJOO), Hypercontractile Esophagus (HE), Distal Esophageal Spasm (DES) and other minor disorders. Physiopathological testing encompasses High-Resolution Manometry (HRM), 24-H esophageal pH-impedance testing, Functional Lumen Imaging Probe (FLIP) assessment. All these tests are designed to provide a clear phenotyping of esophago-gastric disorders related to reflux or obstructive esophageal symptoms, either in naïve patients, as well as after foregut surgery (particularly anti-reflux surgery, achalasia/primary motility disorders treatment).

Participants needed: 10,000
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: IRCCS San RaffaeleUpdated: Apr 2, 2026Locations: 1Duration: 10 Years
Eligibility criteria

Participant is willing and able to give informed consent for participation in th... [+4]

Age < 18 years [+1]

Status: Recruiting

Compassionate Use of Domperidone for Refractory Gastroparesis

The purpose of this program is to allow the use of domperidone in children from 12 to 21 years of age with symptoms related to motility disorders and Gastroesophageal reflux disease (GERD) who have failed all the standard treatments for their condition.

Participants needed: 20
Trial details
Age: 12-21Biological sex: AllType: InterventionalSponsor: Jose CocjinUpdated: Mar 24, 2026Locations: 1
Eligibility criteria

Male or female [+9]

History of, or current, arrhythmias including ventricular tachycardia, ventricul... [+6]

Status: Recruiting

A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks

Primary Objective • To compare the healing rates of LA grade B or higher reflux esophagitis at 8 weeks among patients treated with Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg once daily. Secondary Objectives * To assess the improvement in reflux symptoms using the GERD-Q score at 8 weeks. * To evaluate the incidence of adverse events across treatment groups.

Participants needed: 414
Trial details
Age: 18-75Biological sex: AllType: InterventionalSponsor: Asian Institute of Gastroenterology, IndiaUpdated: Mar 6, 2026Locations: 1
Eligibility criteria

Adults ≥18 years of age. [+3]

Previous or ongoing treatment with Vonaprazan or Esomeprazole in the last 4 week... [+6]

Status: Recruiting

Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.

This study aims to evaluate pharmacokinetic profile, safety and establish bioequivalence of the investigational drug Trimedat® 76,95 mg orally disintegrating tablets compared to the reference drug Trimedat® 100 mg tablets in healthy volunteers under fasted conditions.

Participants needed: 36
Trial details
Phase: Phase 1Age: 18-45Biological sex: AllType: InterventionalSponsor: Valenta Pharm JSCUpdated: Feb 19, 2026Locations: 1
Eligibility criteria

Voluntarily and personally signed informed consent form by a healthy volunteer o... [+37]

Withdrawal of the volunteer from further participation in the study; [+11]

Status: Recruiting

Mechanisms Preventing Pharyngeal Reflux

The overall goal is to define and characterize the manometric characteristics of UES incompetence associated with objectively documented pharyngeal reflux. The investigators will use endoscopic reflux detection as gold standard.

Participants needed: 300
Trial details
Age: 18-85Biological sex: AllType: InterventionalSponsor: Medical College of WisconsinUpdated: Feb 10, 2026Locations: 1
Eligibility criteria

Age 18 to 85 [+6]

Age <18 or >85 [+8]

Status: Recruiting

Heartburn, Gastroesophageal Reflux Disease

Gastroesophageal reflux disease (GERD) is a condition caused by the reflux of stomach contents into the esophagus, presenting with typical symptoms such as heartburn and acid regurgitation. GERD is a chronic condition that affects quality of life, and patients with this condition are known to have a lower quality of life compared to healthy individuals. In particular, nocturnal heartburn can lead to sleep deprivation and affect daily life, as well as overall quality of life. This study aims to evaluate the efficacy of alleviating nocturnal heartburn symptoms in patients with erosive reflux disease (ERD).

Participants needed: 160
Trial details
Phase: Phase 4Age: 19+Biological sex: AllType: InterventionalSponsor: Incheon St.Mary's HospitalUpdated: Dec 23, 2025Locations: 10
Eligibility criteria

Korean adults aged 19 years or older as of the date of written consent [+3]

Those who cannot undergo upper gastrointestinal endoscopy (EGD) [+3]

Status: Recruiting

Utility of Mucosal Impedance Device in Chronic Esophageal Disorders:

Background \& Significance Chronic benign esophageal disorders such as Gastroesophageal reflux disease (GERD) and eosinophilic esophagitis are common gastrointestinal disorders affecting nearly 20% and 0.1% of the population, respectively. Although these conditions are frequent, the diagnosis of GERD or EoE requires complex decision making involving endoscopic examination, histopathological examination, and esophageal pH testing. This translates into significant economic burden; For example, burden due to GERD is about $24 billion annually. Additionally, there may be a delay in the diagnosis of GERD or EoE as Investigators might have to do multiple procedures such as upper endoscopy, esophageal pH testing, etc for the same participant for confirmation of the diagnosis. In addition, there could be overlay between GERD and EoE in the diagnosis which make cause delay in the diagnosis and decision making. Aim: Here, Investigators will plan to identify the diagnostic utility and cost-effectiveness of this novel Mivu device(FDA approved) in the diagnosis of gastroesophageal reflux disease or chronic esophageal inflammatory disorders in participants with reflux symptoms or chronic esophageal symptoms.

Participants needed: 50
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Medical College of WisconsinUpdated: Nov 13, 2025Locations: 1Duration: 1 Year
Eligibility criteria

Presence of esophageal stricture [+5]

Status: Recruiting

Mesh Vs Pledgets for Repair of Paraesophageal Hernia

The goal of this clinical trial is to compare whether the use of Ovitex mesh provides superior reduction in 2-year recurrence compared to pledgeted suture closure (no mesh) for patients undergoing paraesophageal hernia repair at the Cleveland Clinic. The main questions it aims to answer are: * Determine whether there is a difference in 2-year rates of radiographic recurrence with Ovitex versus pledgeted sutures in paraesophageal hernia repair. * Assess patient quality of life (QOL) after paraesophageal hernia repair with pledgets and mesh. A two-tailed research hypothesis will be used to determine whether there are differences between the two arms

Participants needed: 164
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: David KrpataUpdated: Oct 7, 2025Locations: 1
Eligibility criteria

18 years of age or older [+3]

Pregnancy [+4]

Status: Not yet recruiting

Endoscopic Band Ligation for Treating Reflux Disease

GERD is a chronic disease the require different treatment modalities; non have proven long term efficacy with concerns about their safety. The use of band ligation in endoscopy appears safe, repeatable with short learning curve. Placing multiple bands at the Z-line can create a fibrous ring in the distal esophagus acting as a barrier against reflux of gastric content.

Participants needed: 10
Trial details
Age: 18-50Biological sex: AllType: InterventionalSponsor: El Katib HospitalUpdated: Aug 8, 2025Locations: 1
Eligibility criteria

Symptomatic GERD

Any previous surgery for GERD

Status: Recruiting

Real-life Study of Changes of Gastroesophageal Reflux Disease Manifestations Due to Behavioural and Diet Adherence

This study is aimed to investigate the role of long-term diet adherence on manifestations of gastroesophageal reflux disease

Participants needed: 150
Trial details
Age: 18-80Biological sex: AllType: InterventionalSponsor: Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, BiotechnologyUpdated: Aug 3, 2025Locations: 1
Eligibility criteria

willingness to participate (based on the signed informed consent form); [+1]

pregnant or breast-feeding females; [+5]

Status: Recruiting

The Effect of the Reflux Band™ Upper Esophageal Sphincter (UES) Assist Device on Reflux for Lung Transplant Recipients

A prospective, open label, study designed to assess the affect of the Reflux Band® UES Assist Device (Reflux Band) on reflux in patients that have undergone lung transplantation.

Participants needed: 20
Trial details
Age: 18-80Biological sex: AllType: InterventionalSponsor: University of FloridaUpdated: Jul 16, 2025Locations: 1
Eligibility criteria

Clinically stable lung transplant patients(single lung, double lung, or re-trans... [+3]

Currently being treated with another investigational medical device and/or drug [+5]

Status: Recruiting

Truncal Vagotomy in Patients Undergoing Revisional Sleeve Gastrectomy to Gastric Bypass

The purpose of this study is to investigate the efficacy of performing a truncal vagotomy along with a sleeve to bypass revision surgery in reducing the severity and/or incidence of gastroesophageal reflux disease (GERD) post-surgery.

Participants needed: 200
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Baylor Research InstituteUpdated: May 25, 2025Locations: 1
Eligibility criteria

Participating subjects will need to be >18yrs of age and eligible for sleeve to... [+1]

Patients who are under the age of 18. [+1]

Status: Recruiting

Prospective Evaluation of PH-impedance Tracings According to the Wingate Consensus, and Influence on GERD Classification According to the Lyon Consensus

Commonly, in clinical practice an automated analysis of pH-MII tracings is obtained.

Participants needed: 120
Trial details
Age: 18-80Biological sex: AllType: ObservationalSponsor: Universitair Ziekenhuis BrusselUpdated: Mar 19, 2025Locations: 3
Eligibility criteria

Adult patients aged 18 - 80 years old; [+1]

Prior upper GI endoscopy indicative of structural disease (except for oesophagit... [+4]

Status: Recruiting

Anti-Reflux Endoscopic Therapy Using Argon Plasma Coagulation (AREA) in Gastroesophageal Reflux Disease (GERD) Patients: A Single Center, Randomized, Sham, Controlled Trial (The AREA Study)

Background and Rationale: Gastroesophageal reflux disease is affecting 1 in 3 US adults with half experiencing daily symptoms. Per recent data, more than 50% continue to experience daily symptoms despite taking medical therapy and not eligible for surgery. In that small fraction of patients who are eligible for surgery, more than 70% resume taking a medicine for their reflux disease. GERD is common among the US veterans and currently there is a lack of minimally invasive endoscopic therapies for management of GERD. This study will investigate performance of minimally invasive, endoscopic therapy using antireflux mucosal ablation (hybrid argon plasma coagulation) that has been used in other areas of GI tract with efficacy and safety for management of chronic GERD among the US veterans. Objective: The aim of this study is to assess the safety and effectiveness of antireflux mucosal ablation or ARAT (intervention group) in patients with chronic gastroesophageal reflux disease (GERD) symptoms (typical symptoms of GERD, i.e. heartburn or acid reflux/regurgitation at least twice a week) for the last 6 months and objective evidence of reflux disease (positive ambulatory pH study off PPI for 5-7 days) compared to sham procedure (control group).

Participants needed: 18
Trial details
Age: 18-70Biological sex: AllType: InterventionalSponsor: Asian Institute of Gastroenterology, IndiaUpdated: Feb 12, 2025Locations: 1
Eligibility criteria

Patients with chronic GERD symptoms (at least 1 typical symptom of GERD, i.e. he... [+3]

Patients unable to or unwilling to participate or consent [+6]

Status: Recruiting

Stretta Versus Conservative Treatment

Gastroesophageal reflux disease (GERD) is one of the most common diseases of the gastrointestinal tract. Obesity is a significant risk factor for GERD; however, treatment outcomes in obese patients remain challenging. In the Czech Republic, therapeutic options are currently limited to conservative treatment, including pharmacotherapy and lifestyle modifications, or surgical interventions, both of which have known limitations. Stretta is a minimally invasive endoscopic therapy using radiofrequency energy delivered to the esophagogastric junction (EGJ) and cardia, aimed at enhancing the antireflux barrier. This study evaluates the effectiveness and safety of the Stretta procedure compared to conservative treatment in managing GERD. Initially designed to compare outcomes between obese and non-obese populations, the study was expanded to include all GERD patients due to recruitment challenges and the need to meet strict eligibility criteria. These criteria ensure reliable results by focusing on patients with confirmed pathological GERD while excluding those with hiatal hernias ≥ 2 cm, severe esophagitis, or functional esophageal disorders such as hypersensitivity. The study aims to provide comprehensive data on the use of Stretta in the Czech Republic and its role in GERD management.

Participants needed: 50
Trial details
Age: 18-70Biological sex: AllType: InterventionalSponsor: Military University Hospital, PragueUpdated: Jan 7, 2025Locations: 1
Eligibility criteria

Not listed

Status: Recruiting

9-Step Magnetic Bariatric Revisional Surgery

RYGB represents one of the best alternatives for weight loss in obese patients achieving a weight loss of up to 60% and a resolution of comorbidities of 70%. Revision surgery contemplates multiple techniques including the conversion from one surgical technique to another, structural changes to the primary technique, among others. GERD is now a long-term problem for patients who have undergone LGS. RYGB is one of the best techniques to resolve this problem.

Participants needed: 500
Trial details
Age: 18-65Biological sex: AllType: ObservationalSponsor: Unidad Internacional de Cirugia Bariatrica y MetabolicaUpdated: Jul 11, 2022Locations: 1
Eligibility criteria

Older than 18 years [+3]

Uncontrolled co-morbidities [+3]